156 related articles for article (PubMed ID: 2413370)
1. The neuropharmacological profile of N-methyl-N-propargyl-2-aminotetralin: a potent monoamine oxidase inhibitor.
Hazelhoff B; De Vries JB; Dijkstra D; de Jong W; Horn AS
Naunyn Schmiedebergs Arch Pharmacol; 1985 Jul; 330(1):50-8. PubMed ID: 2413370
[TBL] [Abstract][Full Text] [Related]
2. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
Lamensdorf I; Youdim MB; Finberg JP
J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
[TBL] [Abstract][Full Text] [Related]
3. Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats.
Kato T; Dong B; Ishii K; Kinemuchi H
J Neurochem; 1986 Apr; 46(4):1277-82. PubMed ID: 2419508
[TBL] [Abstract][Full Text] [Related]
4. N-methyl,N-propargyl-2-aminotetralins:novel dopamine agonists with monoamine oxidase inhibiting properties.
Hazelhoff B; De Vries JB; Dijkstra D; Mulder TB; Horn AS
Eur J Pharmacol; 1985 Feb; 109(2):229-40. PubMed ID: 3922776
[TBL] [Abstract][Full Text] [Related]
5. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
Karoum F
Br J Pharmacol; 1987 Feb; 90(2):335-45. PubMed ID: 3103805
[TBL] [Abstract][Full Text] [Related]
6. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
[TBL] [Abstract][Full Text] [Related]
7. The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation.
Braestrup C; Andersen H; Randrup A
Eur J Pharmacol; 1975 Nov; 34(1):181-7. PubMed ID: 1241962
[TBL] [Abstract][Full Text] [Related]
8. Reversibility of the interaction of CGP 11305 A with MAO A in vivo.
Waldmeier PC; Feldtrauer JJ; Stoecklin K; Paul E
Eur J Pharmacol; 1983 Oct; 94(1-2):101-8. PubMed ID: 6197309
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of rat brain monoamine oxidase type A by 2-aminotetralin and tetrahydroisoquinoline analogues of dopamine.
Feenstra MG; van der Velden T; Dijkstra D; Hommes OR; Horn AS
Pharm Weekbl Sci; 1983 Aug; 5(4):131-3. PubMed ID: 6622205
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition by amiflamine of monoamine oxidase type A in rat brain, liver and duodenum.
Ask AL
Naunyn Schmiedebergs Arch Pharmacol; 1984 Aug; 327(1):56-63. PubMed ID: 6493351
[TBL] [Abstract][Full Text] [Related]
11. Design and early clinical evaluation of selective inhibitors of monoamine oxidase.
Palfreyman MG; McDonald IA; Bey P; Schechter PJ; Sjoerdsma A
Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(6):967-87. PubMed ID: 3266532
[TBL] [Abstract][Full Text] [Related]
12. Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain.
Waldmeier PC; Baumann PA
Naunyn Schmiedebergs Arch Pharmacol; 1983 Sep; 324(1):20-6. PubMed ID: 6195533
[TBL] [Abstract][Full Text] [Related]
13. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain.
Waldmeier PC; Delini-Stula A; Maître L
Naunyn Schmiedebergs Arch Pharmacol; 1976; 292(1):9-14. PubMed ID: 934359
[TBL] [Abstract][Full Text] [Related]
14. Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens.
Finberg JP; Tenne M
Br J Pharmacol; 1982 Sep; 77(1):13-21. PubMed ID: 6127132
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of types A and B monoamine oxidase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Fuller RW; Hemrick-Luecke SK
J Pharmacol Exp Ther; 1985 Mar; 232(3):696-701. PubMed ID: 3871853
[TBL] [Abstract][Full Text] [Related]
16. The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
Meiring L; Petzer JP; Legoabe LJ; Petzer A
Bioorg Med Chem Lett; 2022 Jul; 67():128746. PubMed ID: 35447344
[TBL] [Abstract][Full Text] [Related]
17. Effects of monoamine oxidase inhibitors on levels of catechols and homovanillic acid in striatum and plasma.
Hovevey-Sion D; Kopin IJ; Stull RW; Goldstein DS
Neuropharmacology; 1989 Aug; 28(8):791-7. PubMed ID: 2506486
[TBL] [Abstract][Full Text] [Related]
18. Effects of clorgyline and (-)deprenyl on the deamination of normetanephrine and noradrenaline in strips and homogenates of the canine saphenous vein.
Caramona MM; Osswald W
Naunyn Schmiedebergs Arch Pharmacol; 1985 Feb; 328(4):396-400. PubMed ID: 3921855
[TBL] [Abstract][Full Text] [Related]
19. On the reversibility of reversible MAO inhibitors.
Waldmeier PC
Naunyn Schmiedebergs Arch Pharmacol; 1985 May; 329(3):305-10. PubMed ID: 4022138
[TBL] [Abstract][Full Text] [Related]
20. Identification of kaempferol as a monoamine oxidase inhibitor and potential Neuroprotectant in extracts of Ginkgo biloba leaves.
Sloley BD; Urichuk LJ; Morley P; Durkin J; Shan JJ; Pang PK; Coutts RT
J Pharm Pharmacol; 2000 Apr; 52(4):451-9. PubMed ID: 10813558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
